Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 2 of about 2   

Articles published

DVAX 21.05 -0.94 (-4.27%)
price chart
FDA Approval of Dynavax's (DVAX) Groundbreaking Hep-B Vacccine Could Double ...
With a current market value of $800 million and the market for hep-B vaccines at about $1.5 billion, sales of Dynavax's proposed vaccine getting about half the market share by 2018 could double the value of the company. Shares are up about 4 percent ...
Andrew Gengos out, John Walker in as Neuraltus CEO
Andrew Gengos, who led Neuraltus Pharmaceuticals Inc. into a Phase II trial of its experimental treatment for Lou Gehrig's disease, has left the company.